Global High-Priority Regulatory Events — March 30, 2026

30-03-2026

OneMedNet Corp reported total revenue of $1,359 thousand for the year ended December 31, 2025, up 111% YoY from $643 thousand, driven by a 329% surge in data delivery revenue (Real-World Data) to $1,254 thousand; however, subscription revenue (BEAM) declined sharply 70% to $105 thousand. The net loss narrowed 72% to $2,801 thousand from $10,129 thousand, benefiting from $5,569 thousand gain on troubled debt restructurings and other non-operating income, though gross margins remained negative at $(503) thousand (worsened 79% YoY) and the company faces going concern doubts amid bitcoin holdings risks. Target markets include Imaging AI, medical device companies, and pharmaceutical companies, with the Real World Evidence market projected to grow from $2.62B in 2024 to $4.55B by 2030 at 8.2% CAGR.

• ·Cost of revenue increased to $1,862 thousand (137% of revenue) from $924 thousand (144% of revenue).
• ·Company highlights risks including going concern, revenue decline reversal, IP protection, bitcoin volatility, and third-party supplier reliance.
• ·Long-term strategies focus on global reach expansion and sales network growth targeting Imaging AI, medical device, and pharmaceutical companies.

30-03-2026

Ingevity Corporation, along with Ingevity Holdings SRL and Ingevity UK Ltd, entered into a Second Amendment and Restatement Agreement dated March 26, 2026, amending their existing credit agreement to establish new Revolving Commitments totaling $750 million, with proceeds used to repay all outstanding revolving loans under the prior facility. The transaction involves JPMorgan Chase Bank, N.A. as Administrative Agent and other lenders, with effectiveness subject to standard conditions including legal opinions, solvency certificates, and repayment of prior obligations. No comparative financial metrics or performance declines are disclosed in the filing.

• ·Existing Credit Agreement originally dated June 23, 2022
• ·Amendment Arrangers: JPMorgan Chase Bank, N.A., BofA Securities, Inc., Citizens Bank, N.A., PNC Bank, National Association, TD Securities (USA) LLC
• ·Legal opinions required from Wachtell, Lipton, Rosen & Katz, McGuireWoods LLP, Loyens & Loeff CVBA, NautaDutilh BV/SRL, Cahill Gordon & Reindel (UK) LLP
• ·Engagement Letter dated February 19, 2026

30-03-2026

AIxCrypto Holdings reported total assets of $31,279,846 as of December 31, 2025, up significantly from $4,686,519 in 2024, driven by cash and cash equivalents rising to $19,332,707 and new digital assets of $10,250,497, bolstered by $40,991,044 in financing activities including $4.5 million from Series A-3 Preferred and substantial Series B Preferred issuances. However, the company posted a larger net loss attributable to shareholders of $19,528,742 in 2025 versus $6,346,795 in 2024, with total expenses increasing 129% to $13,202,096 due to higher general and administrative costs and a $4,195,000 credit loss expense, alongside a $3,588,106 net loss on digital assets. Stockholders’ equity grew to $27,950,609 from $2,679,036, but operating cash use worsened slightly to $(6,951,458).

• ·Short-term notes receivable net: $343,060 (2025) vs $2,010,692 (2024), after allowance of $4.6M (2025) vs $360,000 (2024).
• ·Related party payable: $1,648,945 (2025) vs $0 (2024).
• ·Issuance of $4,166,900 notes receivable to a publicly traded entity from Apr 2024-Dec 2025 at 18% interest.
• ·Secured Convertible Note $264,000 principal (+$44,000 OID) issued Apr 2025, repaid Jan 2026.
• ·Subscription agreement Sept 19, 2025 for $41M: issued 337,432 common shares and 17,783 Series B shares by Sept 29, 2025.

30-03-2026

Vine Hill Capital Investment Corp. shareholders overwhelmingly approved the business combination with CoinShares International Limited at the March 27, 2026 extraordinary general meeting, with 92.6% of votes cast in favor of the Business Combination Proposal (22,095,264 For vs. 1,764,990 Against). The company notified Nasdaq on March 24, 2026, of its intent to voluntarily delist its units (VCICU), Class A ordinary shares (VCIC), and warrants (VCICW) following the merger closing, with Odysseus Holdings Limited's ordinary shares and warrants expected to list on Nasdaq thereafter. The transaction is anticipated to close on March 31, 2026, subject to customary conditions including Jersey regulatory approvals.

• ·Shareholder Meeting quorum: holders of 16,526,920 Class A and 7,333,334 Class B ordinary shares present, representing 81.342% of voting power as of record date March 2, 2026.
• ·All Shareholder Proposals approved, including SPAC Merger Proposal (identical vote to Business Combination), Organizational Document Proposals (some with 150,000 abstentions), and NTA Proposal (23,685,207 For, 25,047 Against, 150,000 Abstain).
• ·Registration Statement on Form F-4 (No. 333-293885) declared effective March 16, 2026; Proxy Statement mailed same day.
• ·Merger structure: SPAC merges into SPAC Merger Sub (Odysseus (Cayman) Limited) on March 30, 2026, followed by scheme of arrangement acquiring CoinShares on March 31, 2026.

30-03-2026

IL&FS Financial Services Limited intimated a default to the Bombay Stock Exchange on servicing obligations for Series 2016-VI bonds (ISIN: INE121H07AT8), specifically failing to redeem principal of ₹70,00,00,000.00 and pay interest of ₹6,17,80,273.97, both due March 30, 2026. This represents a material credit event with no offsetting positive developments mentioned.

• ·Company Code: 10191

30-03-2026

OnKure Therapeutics entered into a securities purchase agreement on March 27, 2026, for a private placement expected to generate approximately $150.0 million in gross proceeds through the sale of 26,713,636 shares of Class A common stock at $4.15 per share and pre-funded warrants to purchase 9,430,959 shares at $4.1499 per underlying share, with closing anticipated on March 31, 2026. The company elected Dr. Liam Ratcliffe, affiliated with lead investor AI Biotechnology LLC, as a Class I director effective upon closing, and plans to use proceeds for preclinical/clinical development of next-generation PI3Kα inhibitors OKI-345 and OKI-355, with IND submissions targeted for H1 2027. However, despite progress in the PIKture-01 trial (completed dose escalations with n=38 single-agent and n=33 + fulvestrant), the company will not pursue further independent clinical development of OKI-219.

• ·Private Placement closing subject to customary conditions on March 31, 2026.
• ·180-day lock-up for executives/directors and Company on share issuances post-Closing.
• ·Registration Statement to be filed within 30 days after Closing, with effectiveness targets of 90-120 days.
• ·Pre-Funded Warrants exercisable at $0.0001 per share, no expiration until fully exercised.
• ·Phase 2 dose evaluation in PIKture-01 (OKI-219 triplets) to complete in 2026; mature data presentation by year-end.
• ·Dr. Ratcliffe to receive standard non-employee director compensation per Company policy.

30-03-2026

NiSource Inc.'s 2026 Proxy Statement outlines the virtual annual meeting on May 11, 2026, seeking stockholder approval to elect 12 director nominees, advisory approval of Named Executive Officer compensation (following 97% support in 2025 Say-on-Pay vote), and ratification of Deloitte & Touche LLP as independent auditors for 2026. The company, serving 3.8 million natural gas and electric customers across six states with 7,700 employees, emphasizes strong governance practices including majority voting, proxy access, separate Chair and CEO, and a Net Zero GHG emissions goal by 2040. No declines or flat metrics are reported in this governance-focused filing.

• ·Annual meeting: May 11, 2026, 10:30 a.m. Central Time, virtual via www.virtualshareholdermeeting.com/NI2026
• ·Record date: Close of business on March 16, 2026
• ·Proxy materials first sent: March 30, 2026
• ·Governance highlights: All independent directors except CEO; annual Say-on-Pay votes; no repricing of options, hedging/pledging, or single-trigger change-in-control vesting
• ·Local brands serve customers in Indiana, Ohio, Pennsylvania, Maryland, Virginia, and Kentucky

30-03-2026

Bangalore Fort Farms Limited filed an Open Offer document on March 30, 2026. The content of the filing is unreadable due to encoding issues or corruption, preventing extraction of specific details such as acquirers, offer price, share volumes, or timelines. No financial metrics, performance data, or comparisons are available from the provided text.

• ·Filing Type: Open Offer
• ·Filing Date: March 30, 2026

30-03-2026

Costamare Bulkers Holdings Ltd filed its 20-F Annual Report on March 30, 2026, disclosing as of March 16, 2026, an owned fleet of 31 dry bulk vessels (including one agreed to sell and one to acquire) with total capacity of 2,846,000 dwt, plus 19 chartered-in vessels with 2,229,000 dwt capacity and two Kamsarmax vessels under construction for charter-in by CBI. Key risks highlighted include potential oversupply reducing charter rates and profitability, substantial capital expenditures to maintain the fleet that may limit cash for dividends, stringent debt covenants such as a 0.75:1 liabilities-to-assets ratio and minimum cash of $30 million or 3% of bank debt, and challenges in securing favorable financing.

30-03-2026

Genasys Inc. (NASDAQ: GNSS) appointed Larry Hagenbuch to its Board of Directors effective March 30, 2026, where he will serve as Chair of the Audit Committee. Mr. Hagenbuch, an operating partner at Crossplane Capital, brings extensive audit, financial oversight, operational, and restructuring experience from prior roles including audit chair at HireQuest (HQI) and Optex Systems, interim C-level positions at Huron Consulting, and positions at GE, GE Capital, and J. Hilburn. CEO Richard Danforth highlighted Hagenbuch's qualifications to support scaling growth amid opportunities like the Puerto Rico Dams Early Warning System project.

• ·Mr. Hagenbuch began career in U.S. Navy as weapons officer on USS Reuben James (FFG-57).
• ·Earned BS in Mechanical and Materials Engineering from Vanderbilt University and MBA from Wharton School at University of Pennsylvania.
• ·Genasys covers more than 155 million people in all 50 U.S. states and over 100 countries worldwide.
• ·References risks including Puerto Rico project funding uncertainties, geopolitical unrest, and need for additional capital in forward-looking statements.

30-03-2026

30-03-2026

Lupin's wholly-owned subsidiary Nanomi B.V. increased its stake in Multicare Pharmaceuticals Philippines, Inc. (MPPI) from 51% to 56.28% following MPPI's buyback of 2,813,811 equity shares from existing shareholders using retained earnings. MPPI, engaged in pharmaceuticals trading and distribution in the Philippines, reported FY25 turnover of PHP 2,096.6 million, down 10.8% YoY from PHP 2,351.2 million in FY24, with net worth at PHP 1,265.5 million as of March 31, 2025. While the stake increase strengthens Nanomi's control, MPPI's recent turnover decline highlights softer performance.

• ·MPPI headquartered in Philippines, incorporated November 09, 2001.
• ·No regulatory approvals required; transaction at arm's length with no promoter/group interest.
• ·Nanomi did not participate in the buyback.

30-03-2026

Promoters IndusInd International Holdings Limited (IIHL) and IndusInd Limited (IL) released pledges on 3,17,85,006 shares (4.08% of total share capital) and 2,79,78,546 shares (3.59% of total share capital) respectively on March 27, 2026, reducing their encumbered holdings to NIL post-release. Total promoter shareholding stands at 11,75,16,010 shares (15.08% of paid-up capital), with pre-release encumbrance at 50.86% of promoter holding. However, other existing encumbrances from prior pledges (e.g., dated September 2021 to February 2024) remain in place with Barclays Bank PLC and Deutsche Bank AG.

• ·Disclosure reported to exchanges on March 28, 2026; filing date March 30, 2026.
• ·Encumbrances released for 'Release of Pledge'; no specific reasons beyond N.A., but existing pledges were for top-up security or global business investments.
• ·Pre-release, encumbered shares exceeded 50% of promoter holding but under 20% of total share capital.
• ·Other existing encumbrances include pledges created September 12, 2021; April 15, 2021; October 20, 2023; December 27, 2023; February 20, 2024 (partially released).

30-03-2026

AV AC DC Renew Private Limited, holding 55.25% (1,42,05,278 shares) in Ampvolts Limited, created a pledge on 5,40,541 equity shares (3.80% of its holding and 2.10% of total share capital) in favor of Mufin Green Finance Limited on February 23, 2026, for a working capital loan availed by the company. This is the first encumbrance on these shares, with no prior pledges reported. The disclosure was filed with BSE on March 28, 2026.

• ·Pledge created for working capital loan availed by Ampvolts Limited
• ·Encumbered shares represent less than 50% of promoter shareholding and less than 20% of total share capital
• ·No details of existing events or agreements pertaining to encumbrance

30-03-2026

Radhagobind Commercial Limited (CIN: L51909WB1981PLC033680) has intimated the scheduling of its 6th Committee of Creditors (COC) meeting on March 30, 2026, at 4:00 PM, at Baithussalam, Kannur, Kerala, and via video conferencing, chaired by Resolution Professional Adv. Najeeb T P. The agenda covers progress on the Corporate Insolvency Resolution Process (CIRP), actions taken by the IRP, revision of resolution plans, and other related matters. This follows NCLT Kolkata Bench appointments of IRP on October 30, 2025, and RP on January 27, 2026, indicating ongoing insolvency proceedings with no resolution yet achieved.

• ·NCLT orders: CP (IB)/71/KB/2025 dated 30.10.2025 (IRP appointment); IA (I.B.C)/90(KB)2026 dated 27-01-2026 (RP appointment).
• ·Meeting venue: Baithussalam, Balankinar, Kattampally Road, Near Indus Motors Maruthi Service Centre, Kannur 670011, Kerala.
• ·Contact: najetpip@gmail.com, radhagobindcirp2025@gmail.com, Mob: 91-9846603236.
• ·Scrip Codes: BSE 030070, CSE 539673.

30-03-2026

Fineotex Chemical Limited has announced the closure of the trading window for dealing in its securities from Wednesday, April 1, 2026, until the end of 48 hours after the declaration of financial results for the quarter and year ended March 31, 2026, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. This restriction applies to all Directors, Designated Employees, and their immediate relatives. The company has communicated this to relevant parties and posted it on www.fineotex.com.

• ·Company codes: BSE 533333, NSE FCL
• ·Filing communicated to Listing Departments at BSE (P.J. Towers, Dalal Street, Mumbai – 400 001) and NSE (Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai - 400051)

30-03-2026

Catalyst Trusteeship Limited disclosed under SEBI SAST Regulations the creation of encumbrance (pledge) over 1,06,50,00,000 equity shares (18.13% of total share/voting capital) of Ashok Leyland Limited held by HAL, moving from NIL prior encumbrance to 18.13% post-creation. This pledge serves as security for a USD 1,445,000,000 term loan facility availed by co-borrowers QHH, IIHL, IndusInd Limited, and HAL from lenders including J.P. Morgan, Barclays, Citibank, and Deutsche Bank, via a margin loan agreement dated 27 March 2026. No change in voting rights or other holdings.

• ·Pledge recorded in depository system pursuant to share pledge agreement dated 27 March 2026 between HAL and Onshore Security Agent.
• ·Acquirer (Catalyst Trusteeship Limited) does not belong to Promoter/Promoter group.
• ·Mode of acquisition: Creation of encumbrance.

30-03-2026

Promoter Vurakaranam Ramakrishna of IIRM Holdings India Limited executed a Non-Disposal Undertaking dated March 28, 2026, encumbering 2,00,00,000 equity shares (29.35% of total share capital) in favor of Axis Trustee Services Limited. This encumbrance relates to Senior, Unrated, Redeemable Secured Non-Convertible Debentures of ₹65,00,00,000 issued by the company's material wholly-owned subsidiary, India Insure Risk Management and Insurance Broking Services Private Limited, with shares valued at ₹161,66,00,000 providing a security coverage ratio of 2.49. The promoter's total holding stands at 39,190,452 shares (57.51% of total share capital), with the encumbered shares comprising 51.03% of his holding.

• ·Encumbrance reported to BSE and CSE on March 30, 2026.
• ·Borrowed amount to be utilized for organic and inorganic growth of the issuer subsidiary.
• ·No prior encumbrances mentioned for the promoter.

30-03-2026

Accelerant Holdings, an emerging growth company under the JOBS Act, has issued its proxy statement for the hybrid 2026 Annual General Meeting on May 12, 2026, at 10:00 a.m. BST in London or via webcast, with pre-registration required at https://web.viewproxy.com/arx/2026. Shareholders of record as of March 13, 2026, will vote on electing three Class I directors for three-year terms expiring in 2029 and ratifying PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026. As of the record date, 222,160,004 common shares are outstanding, comprising 116,757,858 Class A shares (1 vote each) and 105,402,146 Class B shares (10 votes each), with a simple majority quorum required.

• ·Quorum requires holders of a simple majority of common shares present in person or by proxy.
• ·Proxy deadlines: mail by May 11, 2026; internet at www.AALvote.com/ARX by 11:59 p.m. ET on May 11, 2026.
• ·Election of directors requires simple majority of votes cast; ratification of PwC requires majority of votes cast at meeting with quorum.
• ·No cumulative voting in director elections; abstentions and broker non-votes do not impact proposals.

30-03-2026

General Enterprise Ventures, Inc. reported revenue of $2,381,407 for the year ended December 31, 2025, marking a 195% increase from $808,372 in 2024. However, operating expenses surged 209% to $18,877,398, other expenses skyrocketed 1,190% to $20,341,652, and the net loss widened dramatically by 435% to $36,837,643 from $6,881,722. The company highlighted ongoing risks including high leverage, stock volatility, dilution from share issuances, and challenges in achieving profitability.

• ·Recent sales of unregistered securities included 220,000 shares for IP acquisition valued at $1,775,400 from Breakthrough Chemistry, Inc.
• ·346,127 shares issued via cashless conversion of 359,375 warrants.
• ·500,000 shares issued upon conversion of 150,000 shares of Series C Convertible Preferred Stock.
• ·475,862 shares issued for conversion of $1,071,821 in debt and accrued interest.
• ·55,333 shares issued for services valued at $443,377.

30-03-2026

The Committee of Independent Directors (IDC) of Swarnsarita Jewels India Limited unanimously recommends the Open Offer by Acquirers Mr. Mahendra Madanlal Chordia, Mrs. Asha M. Chordia, Mr. Sunny Mahendra Chordia, and PAC Swarnsarita Jewellers Private Limited as fair and reasonable at ₹32.15 per equity share. The offer targets up to 47,94,987 fully paid-up equity shares of face value ₹10 each, representing 22.97% of the Target Company's Voting Share Capital, in compliance with SEBI (SAST) Regulations, 2011. Public shareholders are advised to independently evaluate and take an informed decision on the offer.

• ·Public Announcement (PA) dated January 22, 2026; Detailed Public Statement (DPS) dated January 30, 2026; Letter of Offer (LoF) dated March 18, 2026.
• ·IDC meeting held on March 28, 2026; no IDC member trading in Target Company or PAC shares in 12 months prior to PA or from PA to recommendation date.
• ·IDC members hold no equity in Target Company, are not directors/shareholders of PAC, and have no contracts/relationships with Acquirers or PAC.

30-03-2026

Picard Medical, Inc. reported total net revenues of $4,940 thousand for the year ended December 31, 2025, up 13% YoY from $4,391 thousand, with products revenue increasing 12% to $4,746 thousand and rentals surging 42% to $194 thousand. However, gross loss widened 82% to $(204) thousand due to a 38% rise in product costs to $3,432 thousand despite a 15% decline in rental costs, while net loss grew 28% to $(27,002) thousand driven by 86% higher other expenses including derivative losses up 64% and interest expense up 76%. Operating expenses declined slightly 4% to $13,053 thousand with R&D down 10% and SG&A flat at -2%, and cash balances improved to $7,451 thousand from $96 thousand bolstered by financing activities.

• ·Auditors included explanatory paragraph on going concern due to ability to continue as a going concern.
• ·Cash used in operating activities increased to $15,673 thousand from $11,874 thousand.
• ·No cash used in investing activities in either year.
• ·Total current liabilities decreased to $18,695 thousand from $35,325 thousand.
• ·Preferred stock converted to common stock; no Series A-1 outstanding as of Dec 31 2025.
• ·Stock-based compensation expense $754 thousand in 2025.

30-03-2026

Osisko Development Corp. filed its Form 40-F Annual Report on March 30, 2026. The filing lists the company's Common Shares (no par value, trading symbol ODV) registered on the New York Stock Exchange and Warrants (exercisable for one Common Share at $10.70, trading symbol ODVWZ) on The Nasdaq Stock Market LLC.

30-03-2026

Perimeter Acquisition Corp. I (PMTRW), a blank check company with no operating history or revenues, filed its 10-K on March 30, 2026, disclosing sponsor compensation including 5,911,500 founder shares for $24,460 and 638,000 private placement units, alongside up to $1,500,000 in convertible working capital loans at $10.00 per unit that could cause significant dilution. The filing details 180-day transfer restrictions on founder shares post-IPO or business combination, uncapped reimbursement for sponsor out-of-pocket expenses, and redemption mechanics at approximately $10.00 per share in case of business combination or failure within 24 months of IPO closing. No initial business combination has been completed.

• ·Transfer restrictions on founder shares apply until 180 days after initial business combination or subsequent liquidation/merger/share exchange.
• ·Must complete initial business combination within 24 months from IPO closing or redeem public shares.
• ·No cap on reimbursement of out-of-pocket expenses for sponsor, officers, directors, or affiliates related to business combination activities.
• ·Private placement warrants are non-redeemable.

30-03-2026

HyOrc Corp's 10-K filing discloses a retained earnings deficit of $8,174,862, impairment loss of $300,000, credit loss of $95,747, and net cash used in operating activities of $336,057, reflecting ongoing cash burn and no revenue from its key joint venture. The company is developing an 8 TPD waste-to-methanol pilot facility in Portugal with Start Lda, not yet operational and expected no earlier than July 2026, with plans to expand to 80 TPD subject to financing and risks. Market capitalization stands at $62.3 million based on 737 million outstanding shares trading at $0.0845 per share, with no dividends expected.

• ·Phase 1 pilot facility not operational until July 2026 or later due to permitting, equipment, financing risks
• ·No binding off-take agreements in place for the project
• ·Company not generating revenue under Joint Venture Agreement with Start Lda
• ·No dividends paid historically and none expected
• ·Common stock quoted on OTCQB under ticker HYOR

30-03-2026

ConocoPhillips' 2026 Proxy Statement highlights strong 2025 performance, including full-year production of 2,375 MBOED, $8.0 billion earnings ($6.35 EPS), $19.8 billion cash from operating activities, and $9.0 billion returned to shareholders ($5.0B buybacks, $4.0B dividends) while achieving over $1 billion in Marathon Oil integration synergies and a 15% YoY improvement in Lower 48 drilling efficiencies. The company advanced LNG strategy with 10 MTPA total offtake, met emissions targets including zero routine flaring, and identified $1 billion in additional cost savings on track for 2026. Stockholders are asked to vote on electing 13 directors, ratifying auditors, approving executive compensation advisory, and a stockholder proposal for an independent board chairman at the virtual Annual Meeting on May 12, 2026.

• ·Virtual Annual Meeting on May 12, 2026 at 9:00 a.m. CDT; record date March 18, 2026.
• ·Board recommends FOR election of 13 directors, ratification of auditors, and advisory approval of NEO compensation; AGAINST stockholder proposal for independent board chairman.
• ·Gold Standard Reporting awarded by Oil & Gas Methane Partnership 2.0 (OGMP 2.0) in 2025.
• ·First oil achieved at Surmont Pad 104W-A.

30-03-2026

Our Bond, Inc. (OBAI) entered into Amendment No. 2 to its Securities Purchase Agreement (Equity Line SPA) with Ascent Partners Fund LLC on March 29, 2026, amending terms for Regular Closings (max $1,000,000 or 100% of average daily traded value over prior 10 trading days) and Expanded Closings (up to $5,000,000 under specific volume and price conditions or if average daily traded value exceeds $4,000,000). The amendment allows advance notices anytime during trading days, multiple per day, and includes extended hours trading in key definitions. No financial performance metrics or period comparisons are reported.

• ·Expanded Closing advance notice requires trading volume exceeding 3 times the average daily volume over the prior 10 trading days.
• ·VWAP, daily traded value, and volume definitions now include extended hours trading.
• ·Equity Line SPA effective date clarified as the registration statement effective date for Ascent’s resale of shares.

30-03-2026

RYVYL Inc. reported that RTB Digital, Inc., its proposed merger partner (with Ryvyl as surviving entity), entered a confidential Strategic Partnerships and Investment Terms Agreement to acquire a controlling interest in a strategically aligned company, including a $10 million non-refundable deposit applied to the final purchase price. Upon merger consummation, Ryvyl will assume the agreement through its wholly owned subsidiary RTB. Negotiations on certain terms continue, expected to resolve within 30 days, subject to conditions like funding, additional purchase price payment, and assumption of seller debt.

• ·Date of earliest event: March 25, 2026
• ·Filing date: March 30, 2026
• ·Substantive conditions for Strategic Agreement consummation include funding, payment of additional purchase price, and RTB assuming a portion of seller group outstanding debt

30-03-2026

Soluna Holdings reported total revenue of $29,717 thousand in 2025, down from $38,021 thousand in 2024, driven by a 33% decline in cryptocurrency mining revenue to $11,406 thousand and a 10% drop in data hosting revenue to $16,998 thousand, though high-performance computing service revenue rose 75% to $28 thousand. Operating loss improved 29% to $(33,681) thousand and net loss attributable to Soluna narrowed 16% to $(53,411) thousand, but adjusted EBITDA turned negative at $(13,229) thousand from $942 thousand. Cash balance surged to $76,423 thousand from $7,843 thousand, bolstered by $119,392 thousand in net financing cash flows.

• ·General and administrative expenses excl. dep. & amort. increased 64% to $30,519 thousand.
• ·Interest expense rose 91% to $4,835 thousand.
• ·Gross profit for Soluna Digital was $6,437 thousand across projects.
• ·Net cash used in operating activities was $9,149 thousand.
• ·Purchase of property, plant and equipment was $31,719 thousand.

30-03-2026

Amphenol Corporation entered into an Indenture dated March 30, 2026, with Amphenol Technologies Holding GmbH as issuer, Amphenol Corporation as guarantor, and U.S. Bank Trust Company, National Association as trustee, for the issuance of Notes. This agreement creates a direct financial obligation under Item 2.03. The filing incorporates an Officers’ Certificate establishing the Notes and lists various exhibits including legal opinions.

• ·Exhibits include: 4.1 (Indenture), 4.2 (Officers’ Certificate), 4.3 (Form of Global Note), 5.1 (Opinion of Latham & Watkins LLP, New York), 5.2 (Opinion of Latham & Watkins LLP, Frankfurt), 23.1 and 23.2 (Consents), 104 (XBRL Cover Page)
• ·Incorporated by reference into Registration Statement No. 333-293923

30-03-2026

On March 27, 2026, Dyadic International, Inc. received a Nasdaq deficiency notice for failing to comply with Continued Listing Rule 5550(b), requiring at least $2.5 million in stockholders’ equity, $35 million in market value of listed securities, or $500,000 in net income from continuing operations; the notice has no immediate listing effect but mandates a compliance plan by May 11, 2026, with potential extension to September 23, 2026. The company plans to pursue compliance, likely via the equity threshold, amid ongoing non-compliance with the $1.00 minimum bid price rule (deadline June 17, 2026), either of which could lead to delisting if unresolved.

• ·The deficiency notice has no immediate effect on the listing of DYAI common stock on Nasdaq Capital Market.
• ·Company remains out of compliance with separate minimum bid price requirement, which is unrelated to the new notice.

30-03-2026

A Paradise Acquisition Corp. is pursuing a business combination with Enhanced Ltd., the company behind the Enhanced Games, which has launched an online personalized performance medicine platform offering proprietary supplements, hormone therapy, and peptides like Sermorelin, with plans to expand to seven more if FDA regulations ease on 14 Category 2 peptides. The global peptide therapeutics market is estimated at $52B today, potentially reaching $87B by 2035, with $15B in the US portion of an $80B market, presenting significant opportunities. However, Enhanced has an unproven business model, limited operating history, and minimal revenue to date, alongside regulatory, ethical, and competitive risks.

• ·Inaugural Enhanced Games event scheduled for May 24, 2026 in Las Vegas
• ·Platform launched less than a month ago with positive early DTC metrics (volume, visits, average order size, cart adds) on small numbers
• ·Form S-4 registration statement filed with SEC, including proxy statement/prospectus

30-03-2026

Origin Materials reported total revenues of $18,922 thousand for 2025, down 40% YoY from $31,282 thousand, primarily due to lower product sales, while services revenue dropped to zero from $3 thousand. A massive $195,636 thousand asset impairment drove operating expenses up 204% to $259,634 thousand and net loss to $(249,698) thousand, worsening 198% from $(83,697) thousand; however, Adjusted EBITDA improved to $(43,368) thousand from $(48,367) thousand, and net cash used in operations decreased to $(32,793) thousand from $(50,830) thousand. Total assets shrank to $157,660 thousand from $378,027 thousand, with cash and equivalents at $32,923 thousand.

• ·Stock-based compensation decreased to $8,914 thousand from $10,080 thousand.
• ·Net cash provided by financing activities increased to $10,659 thousand, driven by $15,000 thousand proceeds from convertible notes.
• ·Common stock warrants liability decreased to $167 thousand from $4,566 thousand.

30-03-2026

Aldabra 4 Liquidity Opportunity Vehicle, Inc. (ALOV), a blank check company incepted on July 24, 2025, reported total assets of $285,064, including $23,583 in cash and $261,481 in deferred offering costs, as of December 31, 2025. Total liabilities stood at $338,146, resulting in a shareholder’s deficit of $53,082, with a net loss of $78,082 for the period from inception through December 31, 2025, driven entirely by formation and general administrative expenses and no revenue.

• ·Accounts payable: $11,246 as of December 31, 2025
• ·Accrued expenses: $13,125 as of December 31, 2025
• ·Accrued offering costs: $113,775 as of December 31, 2025
• ·Basic and diluted net loss per Class B ordinary share: ($0.01)
• ·Class B ordinary shares authorized: 20,000,000

30-03-2026

JENA ACQUISITION Corp II, a blank check company with no operating history or revenues, reported total assets of $236,574,719 as of December 31, 2025, driven by $235,449,992 in the Trust Account from 23,000,000 Class A Ordinary Shares at $10.24 per share. For the period from inception (February 24, 2025) to December 31, 2025, it recorded a net loss of $1,836,775 on a $7,286,767 operating loss from formation costs ($386,767) and advisory fees ($6,900,000), partially offset by $5,449,992 in Trust Account interest income, resulting in a shareholders' deficit of $12,700,299. No business combination has been completed, limiting evaluation of future prospects.

• ·Basic and diluted net loss per share of $0.08 for both Class A and Class B Ordinary Shares.
• ·Risks include potential negative interest rates on Trust Account investments, post-combination foreign asset/revenue concentration, and limited shareholder basis for evaluation due to no revenues or operations.

30-03-2026

Remora Capital Corp's 10-K annual report filing highlights its pursuit of regulated investment company (RIC) status under subchapter M of the Internal Revenue Code and business development company (BDC) status under the 1940 Act, including asset composition requirements such as at least 50% in cash equivalents and limited issuer exposures. It references small company thresholds of total assets not exceeding $4 million and capital/surplus of at least $2 million, alongside a gross revenue trigger of $1.235 billion. Risks disclosed include corporate debt market declines reducing portfolio NAV, global economic uncertainties affecting operations, and mandatory debt prepayments limiting portfolio company flexibility.

• ·RIC asset test limits: other securities of any one issuer not more than 5% of assets or 10% of voting securities.
• ·Risk of increased net unrealized depreciation from price declines and illiquidity in corporate debt markets.

30-03-2026

Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported in its 10-K that it has never generated product revenues, anticipates significant ongoing losses, and has substantial doubt about its ability to continue as a going concern due to the need for substantial additional capital. The company is heavily dependent on brilaroxazine, its sole advanced product candidate still in clinical development, with no offsetting positive financial metrics or achievements noted. Risks include material weaknesses in internal controls over financial reporting as of December 31, 2025, potential Nasdaq delisting, reliance on third parties for trials and manufacturing, and significant competition.

• ·Certain warrants are accounted for as liabilities, with changes in value potentially having a material effect on financial results.
• ·No current intention to pay dividends on common stock in the foreseeable future.

30-03-2026

HCM IV Acquisition Corp., a blank check company and shell entity, reported total assets of $160,959, primarily consisting of $25,000 in prepaid expenses and $135,959 in deferred offering costs as of December 31, 2025. The company recorded a net loss of $59,655 from formation and administrative costs for the period from inception (September 5, 2025) through December 31, 2025, resulting in total liabilities of $195,614 (including a $154,819 related party promissory note) and a shareholders' deficit of $34,655, with zero cash on hand at period end.

• ·Entity is a shell company (true), emerging growth company (true), small business (true), and non-accelerated filer.
• ·Entity Central Index Key: 0002089982; Entity Tax ID: 98-1883478.
• ·Address: 85 Washington St, 1F, Stamford, CT 06854; Phone: (203) 930-2200.
• ·Securities listed on NASDAQ.
• ·Basic and diluted net loss per Class B share: $(0.01).
• ·Net cash used in operating activities: $0.

30-03-2026

HCM III Acquisition Corp., a SPAC, reported net income of $2,192,991 for the period from inception (April 15, 2025) through December 31, 2025, driven by $4,298,929 in interest from the Trust Account holding $257,298,929 (25,300,000 Class A shares at $10.17 redemption value). However, the company raised substantial doubt about its ability to continue as a going concern due to only $1,015,282 in cash, operating losses of $914,236, and a shareholders' deficit of $12,787,848, potentially requiring additional funding from its Sponsor amid risks of liquidation if no business combination is completed.

• ·Basic and diluted net income per ordinary share: $0.10 for both Class A and Class B shares.
• ·Over-allotment option exercised in full by underwriters on August 4, 2025.
• ·Net cash used in operating activities: $355,263.
• ·Non-cash deferred underwriting fee payable: $12,045,000.

30-03-2026

Endeavour Silver Corp (EXK) filed its 40-F Annual Report for the year ended December 31, 2025, including audited consolidated financial statements by KPMG LLP for 2025 and 2024, MD&A, and Annual Information Form. Audit fees increased 64.8% YoY to $1,910,726 from $1,159,465, while tax fees and all other fees remained flat at $0 for both years.

• ·Financial statements cover years ended December 31, 2025 and 2024.
• ·Auditor: KPMG LLP (Vancouver, BC, Canada; Auditor Firm ID: 85).
• ·Filing includes Inline XBRL documents (Exhibits 101.INS through 101.PRE).

30-03-2026

Cottonwood Communities, Inc. (CROP) reported NAV of $1,013,012 as of December 31, 2025, reflecting a decline in NAV per share to $11.3574 from $12.0083 at year-end 2024 (-5.4% YoY), though a valuation guideline change added approximately $19.42 million ($0.32 per share). Total revenues fell 2.9% YoY to $153,934 from $158,483, with rental revenues down 4.8% to $138,787, but Core FFO rose sharply 266% to $15,932 from $4,348, and net loss attributable to controlling interests improved to $(4,844) from $(10,956). The company repurchased 1,374,067 shares in Q4 2025 at an average price of about $11.29 per share.

• ·FFO per common share and unit - diluted: $(0.23) in 2025 vs $(0.01) in 2024.
• ·Core FFO per common share and unit - diluted: $0.22 in 2025 (up from $0.07).
• ·Stockholders’ equity: 282,807 as of Dec 31, 2025.
• ·Weighted-average diluted common shares and units: 71,259,649 in 2025 (up from 66,472,501).

30-03-2026

707 Cayman Holdings Ltd., a Cayman Islands exempted company listed on Nasdaq Capital Market since June 9, 2025, filed an F-1 registration statement on March 27, 2026, to register securities with the SEC. The filing discloses significant risks including limited shareholder rights and enforcement challenges under Cayman Islands law, reduced reporting as an emerging growth company and foreign private issuer, increased compliance costs from public listing, and regulatory scrutiny on emerging market companies (e.g., China/Hong Kong) related to PCAOB audit inspections under HFCA Act and AHFCAA, potentially leading to delisting.

• ·Nasdaq listing date: June 9, 2025
• ·Annual report on Form 20-F due within four months of fiscal year-end
• ·Semi-annual financial results via press releases furnished on Form 6-K
• ·SEC/PCAOB joint statements: December 7, 2018; April 21, 2020
• ·HFCA Act: U.S. Senate May 20, 2020; House December 2, 2020
• ·Nasdaq proposals filed: May 21, 2021
• ·Senate AHFCAA passage: June 22, 2021

30-03-2026

Gores Holdings X, Inc., a SPAC, completed its IPO in 2025, raising $358,800,000 in proceeds and funding the Trust Account to $367,742,183, with net income of $920,659 driven by $9,511,647 in interest income. However, the company reported an operational net loss of $1,850,155, a $6,637,800 expense from change in fair value of public warrant liabilities, and basic/diluted net loss per share of $(0.76) across all classes due to accretion of temporary equity, resulting in shareholders' deficit widening to $(31,301,532) from $(40,000). Total assets grew significantly to $368,717,492 from $1,184,632, while cash ended at $619,576.

• ·IPO underwriter's discounts and commissions payment: $250,000
• ·Public warrants derivative liability: $8,162,700 as of Dec 31, 2025
• ·Initial classification of warrant liability - public (non-cash): $1,524,900
• ·Notes payable - related party repaid: $231,901 (after $59,000 proceeds)

30-03-2026

Volato Group, Inc. entered into an ATM Sales Agreement with Curvature Securities, LLC to offer and sell up to $3,700,000 of Class A Common Stock at-the-market. The company provided an update on its pending merger with M2i Global, Inc., where M2i shareholders are expected to receive approximately 85% ownership of the combined company (via ~119.2M shares), resulting in significant dilution for existing Volato shareholders who will hold ~15%. The merger faces risks including stockholder approvals, integration challenges, operational disruptions, and potential failure to realize strategic benefits.

• ·ATM sales made via methods permitted under Rule 415, including directly on NYSE American LLC.
• ·Merger Agreement originally dated July 28, 2025; shelf registration on Form S-3 (File No. 333-290219) effective September 30, 2025.
• ·Company plans to seek stockholder approval for potential reverse stock split to meet NYSE American listing requirements.
• ·Merger closing subject to M2i Global and Volato stockholder approvals, with risks of delays, termination, or adverse business impacts.

30-03-2026

The 21Shares Solana ETF (TSOL), launched on September 17, 2025, reported net assets of $5,735,019 as of December 31, 2025, with 460,000 shares outstanding at a NAV of $12.47 per share, down from higher inflows amid Solana holdings valued at $5,770,226 (cost basis $6,518,230). It generated $203,951 in staking fee income and $176,055 net investment income, but suffered a net realized and unrealized loss of $4,323,701, primarily from $3,578,079 realized loss on Solana sales and $748,004 unrealized depreciation, leading to a $4,147,646 net decrease from operations. Gross contributions totaled $119,956,526 while redemptions were $110,073,861, reflecting high turnover.

• ·Paid-in-capital: $9,882,665
• ·Staking fee payable: $19,187; Sponsor fee payable: $8,334; Block rewards payable: $7,686
• ·Solana purchased: 852,012.1255 quantity for $119,952,208
• ·Solana sold for redemptions: (807,060.9488) quantity for ($110,069,543)